117 related articles for article (PubMed ID: 15864192)
1. Risk factors and long-term course of thyroid dysfunction during antiviral treatments in 221 patients with chronic hepatitis C.
Moncoucy X; Leymarie F; Delemer B; Lévy S; Bernard-Chabert B; Bouché O; Jolly D; Diebold MD; Cadiot G; Thiéfin G
Gastroenterol Clin Biol; 2005 Apr; 29(4):339-45. PubMed ID: 15864192
[TBL] [Abstract][Full Text] [Related]
2. Thyroid disorders during interferon alpha therapy in 625 patients with chronic hepatitis C: a prospective cohort study.
Kabbaj N; Guedira MM; El Atmani H; El Alaoui M; Mohammadi M; Benabed K; Lachkar H; Benaïssa A
Ann Endocrinol (Paris); 2006 Sep; 67(4):343-7. PubMed ID: 17072240
[TBL] [Abstract][Full Text] [Related]
3. Thyroid function and changes in ultrasound morphology during antiviral therapy with pegylated interferon and ribavirin in patients with chronic hepatitis C.
Friedrich-Rust M; Theobald J; Zeuzem S; Bojunga J
J Viral Hepat; 2009 Mar; 16(3):168-77. PubMed ID: 19175874
[TBL] [Abstract][Full Text] [Related]
4. Evolution and predictive factors of thyroid disorder due to interferon alpha in the treatment of hepatitis C.
Gelu-Simeon M; Burlaud A; Young J; Pelletier G; Buffet C
World J Gastroenterol; 2009 Jan; 15(3):328-33. PubMed ID: 19140232
[TBL] [Abstract][Full Text] [Related]
5. The addition of ribavirin to interferon-alpha therapy in patients with hepatitis C virus-related chronic hepatitis does not modify the thyroid autoantibody pattern but increases the risk of developing hypothyroidism.
Carella C; Mazziotti G; Morisco F; Rotondi M; Cioffi M; Tuccillo C; Sorvillo F; Caporaso N; Amato G
Eur J Endocrinol; 2002 Jun; 146(6):743-9. PubMed ID: 12039693
[TBL] [Abstract][Full Text] [Related]
6. Long-term outcomes of thyroid dysfunction in patients with chronić hepatitis C treated with pegylated interferon alpha and ribavirin.
Kozielewicz D; Wietlicka-Piszcz M; Halota W
Przegl Epidemiol; 2017; 71(4):555-569. PubMed ID: 29415534
[TBL] [Abstract][Full Text] [Related]
7. Phenotypes of interferon-α-induced thyroid dysfunction among patients treated for hepatitis C are associated with pretreatment serum TSH and female sex.
Mammen JS; Ghazarian SR; Pulkstenis E; Subramanian GM; Rosen A; Ladenson PW
J Clin Endocrinol Metab; 2012 Sep; 97(9):3270-6. PubMed ID: 22689690
[TBL] [Abstract][Full Text] [Related]
8. Incidence of thyroid dysfunction during interferon alfa-2b and ribavirin therapy in men with chronic hepatitis C: a prospective cohort study.
Bini EJ; Mehandru S
Arch Intern Med; 2004 Nov; 164(21):2371-6. PubMed ID: 15557418
[TBL] [Abstract][Full Text] [Related]
9. [Thyroid dysfunctions in children with chronic hepatitis C during interferon alpha-2b therapy].
Kupś-Rzepecka J; Woźniakowska-Gesicka T; Gołabek V
Przegl Lek; 2011; 68(6):311-5. PubMed ID: 22039668
[TBL] [Abstract][Full Text] [Related]
10. Incidence of dysthyroidism during interferon therapy in chronic hepatitis C.
Benelhadj S; Marcellin P; Castelnau C; Colas-Linhart N; Benhamou JP; Erlinger S; Bok B
Horm Res; 1997; 48(5):209-14. PubMed ID: 9362390
[TBL] [Abstract][Full Text] [Related]
11. Thyroid dysfunction in patients with chronic hepatitis C receiving a combined therapy of interferon and ribavirin: incidence, associated factors and prognosis.
Kee KM; Lee CM; Wang JH; Tung HD; Changchien CS; Lu SN; Wang PW
J Gastroenterol Hepatol; 2006 Jan; 21(1 Pt 2):319-26. PubMed ID: 16460494
[TBL] [Abstract][Full Text] [Related]
12. Effects of combined interferon alpha and ribavirin therapy on thyroid functions in patients with chronic hepatitis C.
Nadeem A; Aslam M; Khan DA; Hussain T; Khan SA
J Coll Physicians Surg Pak; 2009 Feb; 19(2):86-9. PubMed ID: 19208310
[TBL] [Abstract][Full Text] [Related]
13. Thyroid disorders in patients with chronic hepatitis C using interferon-alpha and ribavirin therapy.
Andrade LJ; Atta AM; Atta ML; Mangabeira CN; Paraná R
Braz J Infect Dis; 2011; 15(4):377-81. PubMed ID: 21861010
[TBL] [Abstract][Full Text] [Related]
14. Long-term outcomes and risk factors of thyroid dysfunction during pegylated interferon and ribavirin treatment in patients with chronic hepatitis C infection in Taiwan.
Chang YK; Tseng YT; Chen KH; Chen KT
BMC Endocr Disord; 2019 Apr; 19(1):36. PubMed ID: 30953492
[TBL] [Abstract][Full Text] [Related]
15. Incidence of and risk factors for thyroid dysfunction during peginterferon α and ribavirin treatment in patients with chronic hepatitis C.
Hwang Y; Kim W; Kwon SY; Yu HM; Kim JH; Choe WH
Korean J Intern Med; 2015 Nov; 30(6):792-800. PubMed ID: 26552454
[TBL] [Abstract][Full Text] [Related]
16. [Experiences in antiviral treatment of chronic viral hepatitis B and C in Hungary (1998-2004)].
Pár A; Tornai I; Szalay F
Orv Hetil; 2007 May; 148(18):819-26. PubMed ID: 17468063
[TBL] [Abstract][Full Text] [Related]
17. [Analysis of thyroid dysfunction and influencing factors in chronic hepatitis C patients treated with peg-IFNa-2a and ribavirin].
Huang YX; Chen XY; Ma LN; Yin JM; Ren S; Guo DD; Zheng YH
Zhonghua Gan Zang Bing Za Zhi; 2012 Mar; 20(3):216-20. PubMed ID: 22475143
[TBL] [Abstract][Full Text] [Related]
18. Pegylated interferon (alone or with ribavirin) for chronic hepatitis C in haemodialysis population.
Espinosa M; Hernàndez J; Arenas MD; Carnicer F; Caramelo C; Fabrizi F
Kidney Blood Press Res; 2015; 40(3):258-65. PubMed ID: 25997572
[TBL] [Abstract][Full Text] [Related]
19. Thyroid dysfunction in patients with chronic hepatitis C: virus- or therapy-related?
Vezali E; Elefsiniotis I; Mihas C; Konstantinou E; Saroglou G
J Gastroenterol Hepatol; 2009 Jun; 24(6):1024-9. PubMed ID: 19383078
[TBL] [Abstract][Full Text] [Related]
20. Thyroid dysfunction in Turkish patients with chronic hepatitis C receiving peginterferon plus ribavirin in the period of 2005-2010.
Barut S; Gunal O; Erkorkmaz U; Yildiz F
Braz J Infect Dis; 2012; 16(5):448-51. PubMed ID: 22964290
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
